RxDoctor Payments Data

Peter Buffa, MD

Internal Medicine · Bethpage, NYNPI 1790884344

Payments from drug & device makers

$3,815in general payments, 2019–2025

Across 224 payments — averaging $17.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$416
  • Lilly USA, LLC$395
  • Novartis$342
  • Novo Nordisk$295
  • Boehringer Ingelheim$242
  • Merck$213
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$3,815100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,815 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$332,652
Medicare patients
655
Services billed
11,362

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban118$111,866
JardianceEmpagliflozin67$79,938
OzempicSemaglutide64$78,357
JanuviaSitagliptin Phosphate50$50,858
XareltoRivaroxaban40$41,897
MounjaroTirzepatide19$25,285
FarxigaDapagliflozin Propanediol17$23,417
OxycontinOxycodone Hcl13$19,107
TradjentaLinagliptin27$17,117
Atorvastatin Calcium802$6,950
SynthroidLevothyroxine Sodium140$6,337
Levothyroxine Sodium466$6,241
Metoprolol Succinate389$6,007
Rosuvastatin Calcium348$4,117
Losartan Potassium341$3,391

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$82$113,295140 claims
Boehringer IngelheimJardiance, Tradjenta$242$97,05594 claims
Novo NordiskOzempic$295$78,35764 claims
MerckJanuvia$213$50,85850 claims
Johnson & JohnsonXarelto$97$41,89740 claims
Lilly USA, LLCMounjaro$395$25,28519 claims
AstraZenecaFarxiga$51$23,41717 claims
AbbVieSynthroid$108$6,337140 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$61$6,241466 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Bethpage

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →